{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:49:46Z","timestamp":1761630586880},"reference-count":14,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-\u03b1 (TNF-\u03b1) antagonist and the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-\u03b1 antagonist exposure, so comparison of proportions was imprecise. Only the category \u201climb abnormalities\u201d showed a significantly higher proportion in the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-\u03b1 antagonists could not be confirmed using a population-based congenital anomaly database.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.101316","type":"journal-article","created":{"date-parts":[[2011,7,4]],"date-time":"2011-07-04T12:20:12Z","timestamp":1309782012000},"page":"1871-1874","source":"Crossref","is-referenced-by-count":32,"title":["The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population"],"prefix":"10.3899","volume":"38","author":[{"given":"HUBERTINA J.M.J.","family":"CRIJNS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANNEKE","family":"JENTINK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ESTER","family":"GARNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHRISTINE C.","family":"GISPEN-de WIED","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SABINE M.J.M.","family":"STRAUS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LOLKJE T.W.","family":"de JONG-van den BERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2011,7,1]]},"reference":[{"key":"2018112909265778000_38.9.1871.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.04.016"},{"key":"2018112909265778000_38.9.1871.2","first-page":"1014","article-title":"Tumor necrosis factor inhibition and VATER association: a causal relationship?","volume":"33","author":"Carter","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909265778000_38.9.1871.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080545"},{"key":"2018112909265778000_38.9.1871.4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajmg.1201","article-title":"VATER non-random association of congenital malformations: Study based on data from four malformation registers","volume":"101","author":"K\u00e4ll\u00e9n","year":"2001","journal-title":"Am J Med Genet"},{"key":"2018112909265778000_38.9.1871.5","doi-asserted-by":"publisher","DOI":"10.1148\/126.2.445"},{"key":"2018112909265778000_38.9.1871.6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19970711)71:1<8::AID-AJMG2>3.0.CO;2-V"},{"key":"2018112909265778000_38.9.1871.7","unstructured":"US Food and Drug Administration . Adverse Event Reporting System. Silver Spring, MD. [Internet. Accessed May 11, 2011.] Available from: www.fda.gov\/drugs\/GuidanceComplianceRegulatoryInformation\/surveillance\/adversedrugeffects"},{"key":"2018112909265778000_38.9.1871.8","unstructured":"EUROCAT . EUROCAT Guide 1.3 and reference documents, instructions for the registration and surveillance of congenital anomalies, September 2005. [Internet. Accessed May 11, 2011.] Available from: http:\/\/www.eurocat.ulster.ac.uk\/pdf\/EUROCAT-Guide"},{"key":"2018112909265778000_38.9.1871.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907328"},{"key":"2018112909265778000_38.9.1871.10","unstructured":"European Medicines Agency . London. European public assessment reports: Enbrel. [Internet. Accessed May 11, 2011.] Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000262\/human_med_000764.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125"},{"key":"2018112909265778000_38.9.1871.11","unstructured":"European Medicines Agency . London. European public assessment reports: Humira. [Internet. Accessed May 11, 2011.] Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000481\/human_med_000822.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125"},{"key":"2018112909265778000_38.9.1871.12","unstructured":"European Medicines Agency . London. European public assessment reports: Remicade. [Internet. Accessed May 11, 2011.] Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000240\/human_med_001023.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125"},{"key":"2018112909265778000_38.9.1871.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(73)80024-1"},{"key":"2018112909265778000_38.9.1871.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb031395"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.101316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:59:35Z","timestamp":1543514375000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.101316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,1]]},"references-count":14,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,1]]},"published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.3899\/jrheum.101316"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.101316","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,1]]}}}